A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

NCT03394924 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Biliary Cholangitis

Interventions

DRUG: EDP-305 1 mg
DRUG: EDP-305 2.5 mg
DRUG: Placebo

Sponsor

Enanta Pharmaceuticals, Inc

Collaborators

[object Object]
[object Object]